2025-12-24 - Analysis Report
Here's a comprehensive analysis of Hims & Hers Health Inc. (HIMS) based on the provided data:

**1) Return Rate Comparison**

*   **Ticker:** HIMS (Hims & Hers Health Inc.) - A telehealth company offering personalized health and wellness solutions.
*   **HIMS Cumulative Return:** 129.58%
*   **S&P 500 (VOO) Cumulative Return:** 74.84%
*   **Divergence:** 54.7 (Relative Divergence: 34.5)

**Analysis:** HIMS has significantly outperformed the S&P 500 over the analyzed period. The positive divergence of 54.7 indicates HIMS's superior performance. A relative divergence of 34.5 suggests that this outperformance is not at the extreme high end of its historical range, implying there may be room for further potential.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta   | Cap(B) |
|------------|--------|-------|--------|--------|--------|
| 2019-2021  | -42.0% | 74.4% | -81.0% | 0.0    | 1.5    |
| 2020-2022  | -19.0% | 78.6% | -18.0% | -0.0 | 1.4    |
| 2021-2023  | -65.0% | 78.6% | -67.0% | -0.1 | 2.0    |
| 2022-2024  | 119.0% | 79.4% | 98.0% | -0.0 | 5.4    |
| 2023-2025  | 134.0% | 80.8% | 69.0% | 0.1    | 7.9    |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Fluctuates significantly, with substantial losses in earlier periods followed by strong growth in recent years. This suggests a volatile stock with potentially high risk and reward.
*   **MDD (Maximum Drawdown):** Consistently high drawdowns indicate significant price volatility and downside risk.
*   **Alpha:**  The positive Alpha in the later periods (2022-2024 and 2023-2025) indicates that HIMS has generated returns above what would be expected based on its beta. Negative Alpha in earlier periods suggests underperformance relative to its risk.
*   **Beta:** Beta hovers around zero, suggesting that price is independent of the index, but Beta increased to 0.1 on 2023-2025, suggesting the stock's volatility is slightly correlated to the overall market.
*   **Cap(B) (Market Capitalization in Billions):** Market capitalization is steadily growing, indicating increased investor confidence and company growth.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 35.56
*   **Last Market Data:** Price: 34.8, Previous Close: 35.05, Change: -0.71
*   **5-day SMA:** 35.68
*   **20-day SMA:** 37.36
*   **60-day SMA:** 44.56

**Analysis:** The stock price is currently below both its 20-day and 60-day Simple Moving Averages (SMAs), which may be interpreted as a short-term downtrend. The recent market data shows a slight decrease in price, but current close is higher than last market, showing recover pattern. The 5-day SMA is slightly higher than the current close, suggesting potential resistance in the very near term.

**3) Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 44.60
*   **PPO:** 0.0229
*   **Hybrid Signal:** Buy 100% (Very Safe, MRI: 0.90)
*   **Recent Relative Divergence Change:** -2.7 (Short-term decline)
*   **Expected Return:** 31.3% (Long-term, vs. S&P 500)

**Analysis:**

*   The Medium Investment rating from the MRI suggests a moderate level of risk.
*   The RSI of 44.60 is in neutral territory, not indicating overbought or oversold conditions.
*   The PPO indicates the price momentum is slightly positive.
*   The Hybrid Signal recommends buying, considering it a very safe investment with an MRI of 0.90.
*   The recent decline in relative divergence (-2.7) suggests a short-term pullback in performance relative to the S&P 500.
*   The high Expected Return of 31.3% suggests significant potential upside if held long-term.

**4) Recent News & Significant Events**

*   **Positive Sentiment:** Multiple articles highlight HIMS as a trending stock with room to run, a potential buy, and suggest that market panic is irrational.  The article "3 Healthcare IT Stocks Up More Than 20% in 2025 With More Room to Run" is also supportive.
*   **Share Repurchase Program:** The $250 Million Share Repurchase Program Authorization could boost investor confidence and potentially increase the stock price.
*   **Negative Sentiment:** One article mentions a 5% stock fall in a week, indicating that it would be important to check the companyâ€™s latest performance in the market.

**5) Recent Earnings Analysis**

| Date       | EPS  | Revenue |
|------------|------|---------|
| 2025-11-03 | 0.07 | 0.60 B$ |
| 2025-08-04 | 0.19 | 0.54 B$ |
| 2025-05-05 | 0.22 | 0.59 B$ |
| 2024-11-04 | 0.35 | 0.40 B$ |
| 2025-11-03 | 0.35 | 0.40 B$ |

**Analysis:**

*   Revenue is generally trending upward, indicating increasing sales and market penetration.
*   EPS (Earnings Per Share) fluctuates, but there is overall increasing trend in general.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $0.60B  | 73.80%        |
| 2025-06-30   | $0.54B  | 76.39%        |
| 2025-03-31   | $0.59B  | 73.50%        |
| 2024-12-31   | $0.48B  | 76.81%        |
| 2024-09-30   | $0.40B  | 79.16%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE     |
|--------------|---------|---------|
| 2025-09-30   | $0.58B  | 2.72%   |
| 2025-06-30   | $0.56B  | 7.55%   |
| 2025-03-31   | $0.55B  | 9.01%   |
| 2024-12-31   | $0.48B  | 5.46%   |
| 2024-09-30   | $0.44B  | 17.18%  |

**Analysis:**

*   **Revenue:** Shows a strong upward trend, indicating growth in the company's business.
*   **Profit Margin:** Remains consistently high, suggesting good cost control and strong pricing power.
*   **Equity:** The company's equity is steadily increasing, indicating financial stability and growth.
*   **ROE (Return on Equity):** ROE is volatile, and is showing decreasing trend, indicating a change in how profitable the company is with shareholders' investments.

**7) Comprehensive Analysis (Summary)**

Hims & Hers Health Inc. (HIMS) presents a mixed picture.

*   **Positive Aspects:** The company has significantly outperformed the S&P 500 recently. Revenue is growing, and profitability is high. Analyst sentiment is generally positive, with articles suggesting growth potential and irrational market panic. The company has also announced a share repurchase program.
*   **Negative Aspects:** The stock price has experienced considerable volatility historically, as evidenced by the high MDD figures. There has been a recent short-term decline in relative performance. The current stock price is below its 20-day and 60-day SMAs. Recent decreasing ROE is not a positive sign.

**Overall Conclusion:**

HIMS appears to be a high-growth company with significant potential, but it comes with considerable risk. The company is currently on a positive trajectory with respect to revenue and long-term expected return, but faces short-term headwinds based on market conditions and decreasing ROE. The technical indicators present a mixed picture, and the recent decline in relative divergence is something to monitor.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.